Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durlobactam - Entasis Therapeutics

Next Previous
Drug Profile

Durlobactam - Entasis Therapeutics

Alternative Names: 14C ETX2514; Durlobactam sodium; ETX-2514; ETX-2514-sodium

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics
  • Class Antibacterials; Aza compounds; Esters; Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Tuberculosis
  • No development reported Acinetobacter infections

Most Recent Events

  • 11 Apr 2025 Antimicrobial data from preclinical studies in Enterobacterales species presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID-2025)
  • 15 Feb 2023 Innoviva has patents pending for durlobactam in USA and other countries
  • 15 Feb 2023 Innoviva has patents protection for durlobactam in USA and in several jurisdictions including Australia, the European Union, Canada, China, Hong Kong, Israel, India, Japan, Macau, Mexico, New Zealand, the Philippines, the Russian Federation, Singapore, South Africa, South Korea, Taiwan and the United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top